A Single-Arm, Single-Center, Non-Randomized, Prospective Clinical Study to Evaluate the Safety and Effectiveness of Physician Modified Endograft for Complex Abdominal and Thoracoabdominal Aortic Aneurysm Repair

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The physician modified endograft is intended for treating complex, pararenal, juxtarenal and thoracoabdominal aortic aneurysms requiring coverage of renal arteries, the superior mesenteric artery or the celiac trunk in high-risk patients who do not have an option for endovascular repair with an FDA approved endograft and have an appropriate anatomy. There will be one investigational site with a total of 40 subjects to be enrolled. Time to complete enrollment will be 24 months and the subject follow-up time will be five years from last subject enrollment. The primary safety endpoint is freedom from major adverse events (MAE) at 30 days or during hospitalization if this exceeds 30 days. The primary effectiveness endpoint is the proportion of study subjects with treatment success at one year. The subjects will be followed at one month, six months, one year, and yearly thereafter for a total period of five years. Subjects will be followed up clinically for life. Clinical exam follow up may be phone or video visit with CT scan evaluation and duplex ultrasound as needed. The proportion of treatment group subjects that achieve and maintain treatment success annually to five years will be investigated.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient is \> 18 years of age

• Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)

• Patient is able and willing to sign an Institutional Review Board (IRB) approved Informed Consent Form

• Patient has a complex, juxtarenal, pararenal or thoracoabdominal abdominal aortic aneurysm (Extent I-V) that meets at least one of the following:

‣ Aortic aneurysm with diameter ≥ 5.5cm

⁃ Aortic aneurysm with a history of growth ≥0.5cm in the last 6 months

⁃ Symptomatic aortic aneurysm

• Cannot be treated with a currently available non-modified approved device

• High risk for open surgical repair based on any of the factors below:

∙ Anatomic i. Previous abdominal surgery ii. Previous left-sided thoracotomy (if the proposed open repair would require dissection of the thoracic aorta) iii. Previous aortic surgery

‣ Physiologic i. ASA Category III or higher ii. Age \>70 years iii. Previous myocardial infarction, coronary artery disease, or coronary artery stent iv. Coronary stress test with a reversible perfusion defect v. Congestive heart failure vi. COPD

• Patient has patent iliac or femoral arteries that will allow endovascular access with the physician modified endovascular graft or is suitable for an iliac conduit

• Patient has a suitable non-aneurysmal proximal aortic neck length (seal zone) of ≥ 20 mm

• Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥ 15 mm.

⁃ The resultant repair should preserve patency in at least one hypogastric artery.

⁃ Patient has a suitable non-aneurysmal proximal aortic neck diameter between 15 and 42mm

⁃ Patient has suitable non-aneurysmal distal common iliac diameters between 7 and 20 mm.

• --Exclusion Criteria---

Locations
United States
California
University of California San Diego
RECRUITING
San Diego
Contact Information
Primary
Sina Zarrintan, MD
szarrintan@health.ucsd.edu
8582463003
Backup
Kathleen Groh
kagroh@health.ucsd.edu
8585348103
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2029-12
Participants
Target number of participants: 40
Treatments
Experimental: Physician-Modified Endograft
This is a single arm study used to evaluate the safety and effectiveness of fenestrated and branched techniques for the treatment of patients with a complex, juxtarenal, pararenal or thoracoabdominal abdominal aortic aneurysms (Extent I-V).
Sponsors
Leads: University of California, San Diego

This content was sourced from clinicaltrials.gov